Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 16/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599712 | 0.85 | P2RX7 (0.53) | P2RX7PDK2HDAC4HDAC1HDAC6 | |
| SCHEMBL29572376 | 0.81 | P2RX7 (0.56) | P2RX7PDK2HDAC4HDAC1HDAC6 | |
| SCHEMBL31065923 | 0.80 | P2RX7 (0.51) | P2RX7PDK2HDAC4HDAC1HDAC6 | |
| SCHEMBL601417 | 0.78 | P2RX7 (0.47) | P2RX7PDK2TSHR | |
| SCHEMBL29263884 | 0.75 | P2RX7 (0.44) | P2RX7PDK2HDAC4HDAC1HDAC6 | |
| SCHEMBL28734987 | 0.73 | PDK2 (0.40) | P2RX7PDK2HDAC4HDAC1HDAC6 | |
| SCHEMBL107990 | 0.72 | P2RX7 (0.57) | P2RX7PDK2TACR3 | |
| SCHEMBL25420895 | 0.72 | P2RX7 (0.40) | P2RX7 | |
| SCHEMBL29263895 | 0.70 | P2RX7 (0.47) | P2RX7PDK2HDAC4HDAC1HDAC6 | |
| SCHEMBL28734981 | 0.70 | P2RX7 (0.53) | P2RX7PDK2HDAC4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118103369-A | Pyridolactam derivatives, preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-114907408-B | Heterocyclic compound, intermediate thereof, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-3778573-B1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO LTD (JP) | 2024-04-24 | — | — | EP | disclosed |
| CN-111936468-B | Compounds with anticancer activity | 协和麒麟株式会社 | 2024-03-08 | — | — | CN | disclosed |
| CN-117279908-A | Heteroaryl compounds for the treatment of cognitive disorders | 加的夫大学学院咨询有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-114456173-B | Condensed ring group substituted cyclohexanediimide derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-11629152-B2 | Compound with anticancer activity | KYOWA KIRIN CO., LTD. (JP) | 2023-04-18 | — | — | US | disclosed |
| CN-113880843-B | Heterocyclic compound and application thereof | 武汉朗来科技发展有限公司 | 2023-03-10 | — | — | CN | disclosed |
| US-20230062486-A1 | KRAS G12C INHIBITOR AND PHARMACEUTICAL USE THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2023-03-02 | — | — | US | disclosed |
| CN-111936468-A | Compounds with anti-cancer activity | 协和麒麟株式会社 | 2020-11-13 | — | — | CN | disclosed |
| EP-2773641-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064984-A1 | BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
| US-20110082130-A1 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | LIGAND PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| EP-1998620-B1 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | NEUROGEN CORP (US) | 2011-01-12 | — | — | EP | disclosed |
| US-7795262-B2 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1998620-A4 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | NEUROGEN CORP (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1998620-A2 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | Neurogen Corporation (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007106349-A2 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | HRH3, HRH4, HRH1 | P2RX7 257/4885PDK2 1557/4885HDAC4 769/4885 |
| US-20230062486-A1 | KRAS G12C INHIBITOR AND PHARMACEUTICAL USE THEREOF | KRAS, NRAS, HRAS | P2RX7 3986/4885PDK2 1894/4885HDAC4 4458/4885 |
| US-20110082130-A1 | PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES | HRH3, HRH4, HRH1 | P2RX7 257/4885PDK2 1557/4885HDAC4 769/4885 |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | P2RX7 4800/4885PDK2 1092/4885HDAC4 384/4885 |
| US-11629152-B2 | Compound with anticancer activity | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | P2RX7 4800/4885PDK2 1092/4885HDAC4 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.